Carmell Expands Bio-Aesthetic Portfolio with Elevai Acquisition

Carmell Corporation (NASDAQ: CTCX), a leading bio-aesthetics company focused on skin and hair health, has announced the closing of its acquisition of the skin and hair care business of Elevai Skincare, Inc. (Elevai). This strategic move enables Carmell to expand its bio-aesthetic product portfolio, broaden its commercial footprint, and improve its cash flow. Here's a closer look at the acquisition and its expected benefits.



Expanding the Bio-Aesthetic Product Portfolio

As part of the acquisition, Carmell gains access to Elevai's product portfolio, which generated approximately $2.5 million in revenue for FY2024. This portfolio includes Elevai's stem cell exosome technology, a cutting-edge approach to skincare and hair care. By integrating these products into its offerings, Carmell can provide a more comprehensive range of bio-aesthetic solutions to its customers.

Broadening the Commercial Footprint

The acquisition also includes Elevai's commercial and product development team. This team brings valuable expertise and experience in marketing and selling physician-dispensed skincare and hair care products. By integrating this team into Carmell, the company can leverage their knowledge to expand its commercial footprint and improve its cash flow.

Improving Cash Flow

The acquisition includes the assumption of Elevai's contractual liabilities and trade payables, which can help Carmell optimize its working capital and improve cash flow management. Additionally, the earnout considerations, such as the 5% of net sales from Elevai's existing products paid annually over five years, and the one-time milestone payment of $500,000 if Elevai's hair and scalp products achieve $500,000 in net revenue within 24 months, provide additional cash flow opportunities.



Earnout Structure Incentivizes Future Growth

The earnout structure in the acquisition of Elevai by Carmell incentivizes Elevai's future growth while minimizing Carmell's upfront risk. The 5% of net sales from existing products paid annually for five years aligns Carmell's interests with Elevai's future performance. Additionally, the one-time milestone payment of $500,000 if Elevai's hair and scalp products achieve $500,000 in net revenue within 24 months rewards Elevai for meeting specific revenue targets.

Conclusion

The acquisition of Elevai's skin and hair care business by Carmell is a strategic move that enables the company to expand its bio-aesthetic product portfolio, broaden its commercial footprint, and improve its cash flow. By integrating Elevai's product portfolio and commercial team, Carmell can offer a more comprehensive range of bio-aesthetic solutions to its customers and tap into new markets. The earnout structure incentivizes Elevai's future growth while minimizing Carmell's upfront risk, making this acquisition an attractive opportunity for both companies.